| Literature DB >> 19727989 |
Marshall R Urist, Basil S Strates.
Abstract
This Classic Article is a reprint of the original work by Marshall R. Urist and Basil S. Strates, Bone Morphogenetic Protein. An accompanying biographical sketch of Marshall R. Urist, MD is available at DOI 10.1007/s11999-009-1067-4; a second Classic Article is available at DOI 10.1007/s11999-009-1069-2; and a third Classic Article is available at DOI 10.1007/s11999-009-1070-9. The Classic Article is copyright 1971 by Sage Publications Inc. Journals and is reprinted with permission from Urist MR, Strates BS. Bone morphogenetic protein. J Dent Res. 1971;50:1392-1406.Entities:
Year: 2009 PMID: 19727989 PMCID: PMC2772914 DOI: 10.1007/s11999-009-1068-3
Source DB: PubMed Journal: Clin Orthop Relat Res ISSN: 0009-921X Impact factor: 4.176
Effect of CaCl2 extraction on bone morphogenesis in implants of bone matrix four weeks after implantation
| Solution | mm3 new bone/6 mm3 preimplanted matrix* | mg ash/gm preimplanted matrix |
|---|---|---|
| 0.9% NaCl | 5.0 | 520 ± 51 |
| 0.1 | 5.0 | 550 ± 48 |
| 0.2 | 5.0 | 495 ± 32 |
| 0.6 | 5.0 | 500 ± 58 |
| 1.0 | 4.5 | 480 ± 38 |
| 2.0 | 3.0 | 325 ± 29 |
| 6.0 | 2.0 | 150 ± 12 |
| 6.0 | 0 | 0 |
| 0.6 | 5.0 | 502 ± 45 |
| 0.6 | 4.5 | 490 ± 42 |
| 0.6 | 4.0 | 395 ± 40 |
| 0.6 | 0 | 0 |
* Based on correlated radiographic and quantitative histologic observations.
Fig. 1Demineralized cortical bone matrix, lyophilized and superfixed with 3% glutaraldehyde and 1.3% osmium tetroxide, cut in sections approximately 500 A thick and stained with uranyl acetate and lead citrate. Note large volume of space filled with interfibrillar electron-dense material, presumably proteoglycans (arrows) in the area cut in cross section (X). In longitudinal section (L) overlapping intertwined arrangement of collagen fibril (F) obscures large volume of interfibrillar noncollagenous material in bone matrix.
Fig. 3Rat bone matrix superfixed with glutaraldehyde and stained with 5% phosphotungstic acid and bismuth nitrate. Note bismuth-stained coat on collagen fibrils (arrows) and relatively large volume of interfibrillar space for proteoglycans.
Fig. 4Amorphous structure of old bone matrix after two weeks of exposure to body fluids and apposition of new bone. OC, osteocyte; NB, calcified new bone matrix; NC, uncalcified and precalcified new bone matrix; OM, nonstaining old bone matrix with deposits of mineral at line of contact with new bone.
Fig. 5Structure of earliest deposits of mineral in new bone in another area of implant shown in Fig. 4. MF, osteocyte extension with microfilaments; F, uncalcified cores of collagen fibrils and groups of fibrils; CC, apatite deposits in spaces between and in surface of collagen fibrils; UNBC, uncalcified or precalcified new bone matrix. In cross section, because of interfibrillar space, at least a third of matrix domain is available for occupancy by ground substance including proteoglycans, shown in Figs. 1 to 3.
Bone morphogenetic activity of demineralized matrix treated with enzymes
| Treatment of the preimplanted matrix | mm3 new bone/6 mm3 preimplanted matrix | mg bone ash/gm preimplanted matrix |
|---|---|---|
| Control (no treatment) | 5.0 | 520 ± 51 |
| α-Amylase in phosphate buffer, pH 5.4, at 25 C, 90 hr | 5.0 | 490 ± 40 |
| α-Amylase in phosphate buffer, pH 5.4, at 2 C, 90 hr | 5.0 | 500 ± 10 |
| Phosphate buffer without amylase, at 25 C, 90 hr | 5.0 | 510 ± 40 |
| Phosphate buffer without amylase, at 2 C, 90 hr | 5.0 | 515 ± 20 |
| Trypsin in phosphate buffer, pH 7.6 at 15 C, 8 hr | 0.5 | 50 ± 5 |
| Trypsin in phosphate buffer, pH 7.6, at 15 C, 24 hr | 0 | 0 |
| Trypsin in phosphate buffer, pH 7.6, at 15 C, 48 hr | 0 | 0 |
| Trypsin in phosphate buffer, pH 7.6, at 15 C, 96 hr | 0 | 0 |
| Phosphate buffer without trypsin, at 15 C, 96 hr | 0 | 485 ± 20 |
Yield of new bone in implants of demineralized matrix treated with protein denaturants (four weeks after implantation)
| Agent | mM/liter | mg bone ash/gm preimplanted matrix |
|---|---|---|
| Glutaraldehyde | 0 | 500 |
| 1 | 505 | |
| 2 | 510 | |
| 5 | 450 | |
| 10 | 300 | |
| 100 | 0 | |
| 1000 | 0 | |
| 2000 | 0 | |
| Formaldehyde, (4 weeks after implantation) | 1000 | 0 |
| Formaldehyde, (4 weeks after implantation) | 1800 | 0 |
| Formaldehyde, (4 weeks after implantation) | 2000 | 0 |
| Formaldehyde, (12 weeks after implantation) | 3300 | 10 |
| Formaldehyde-treated lathyritic matrix (4 weeks after implantation) | 1800 | 0 |
| Remazol black | (1% w/v) | 0 |
| Borohydride | 0.5 | 500 |
| 5 | 450 | |
| 50 | 490 | |
| FDNB | 0 | 490 |
| 3 | 460 | |
| 5 | 450 | |
| 10 | 470 | |
| 26 | 210 | |
| 53 | 200 | |
| 268 | 20 | |
| HNO3 | 600 | 0 |
| HNO2 | 600 | 0 |